Jazz Pharmaceuticals(JAZZ) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance – Renee Gala named as President and CEO, effective August 11 – – Total revenues of $1.05 billion in 2Q25 – – Xywav revenues grew 13% year-over-year, with robust net patient adds of 625 quarter-over-quarter – – Zepzelca granted Priority Review in 1L ES-SCLC – ® ® DUBLIN, August 5, 2025 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2025 ...